New approaches to the treatment of dense deposit disease. - Wikidata - awgldk - TriplyDB

New approaches to the treatment of dense deposit disease.

New approaches to the treatment of dense deposit disease.

http://www.wikidata.org/entity/Q36860946

about

Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis Overview of C3 Glomerulopathy Therapeutic regulation of complement in patients with renal disease - where is the promise?De novo membranoproliferative glomerulonephritis III in a renal transplant patient: case report and review of the literature Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion Solution Structure of CCP Modules 10–12 Illuminates Functional Architecture of the Complement Regulator, Factor H Complement Evasion Mediated by Enhancement of Captured Factor H: Implications for Protection of Self-Surfaces from Complement Production of biologically active recombinant human factor H in Physcomitrella C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals.Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome.Inhibiting complement activation on cells at the step of C3 cleavage.Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway.Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions.Treatment of choroidal neovascularisation secondary to membranoproliferative glomerulonephritis type II with intravitreal ranibizumab.Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy.Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement Childhood-onset dense deposit disease: a rare cause of proteinuria Membranoproliferative glomerulonephritis Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice.Complement control protein factor H: the good, the bad, and the inadequate.Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation.C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.Current concepts in C3 glomerulopathy.Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells.Dense deposit disease.Allelic variants of complement genes associated with dense deposit disease.Regulating complement in the kidney: insights from CFHR5 nephropathy.Clinical features and outcomes of 98 children and adults with dense deposit disease.Association of a novel complement factor H mutation with severe crescentic and necrotizing glomerulonephritis.Secondary focal and segmental glomerulosclerosis associated with single-nucleotide polymorphisms in the genes encoding complement factor H and C3.C3 glomerulonephritis associated with monoclonal gammopathy: a case series.Treatment options for C3 glomerulopathy Causes of alternative pathway dysregulation in dense deposit disease.Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association?Characterization of C3 in C3 glomerulopathy.

P2860

Q24615589-EA1202F0-66C3-454F-98E1-E1113209AFCD Q26747262-5DDA69A0-3CB6-4510-8529-00534859CDCB Q26851705-A041A988-A521-4F7E-994B-D9DFD93AD136 Q26860761-8CEEA47F-75CF-4383-BEF9-BEF1A5286153 Q27008508-1F11B201-F537-4F7C-A172-A4FF2A56434A Q27673696-1B971FA6-3C4C-4AE4-B86A-A062AB81C25C Q28268485-1210F9E2-F8DB-48EC-92BD-26BC328AE72E Q28290970-4DEC7962-3BF3-4517-8814-3401F2F66CCE Q30274884-1D959643-47B9-4E26-AF92-FB9D92ACBC7F Q33377727-8588A235-1383-438A-9AF8-4E7162EF74AC Q33378236-B249EC5D-6B17-4E84-B325-73E271E344C7 Q33381183-2F32136A-EF58-4B00-B310-A08D5BB43CE3 Q33381980-FF7AF94D-4B2D-4505-B754-D5F1A92B7CD4 Q33384196-1C052EE7-3C48-4CCD-A1F2-368347B1EC92 Q33396792-FBD244A7-36D0-42CD-94DC-0A01798A1E16 Q33403738-A73228F3-92D7-4918-A199-DFEC69170DD2 Q33405609-65EE2285-F75F-4F03-A1DA-923F9FC49621 Q33743019-3D0A35D3-ED20-4A09-8170-7FBEE57922F9 Q33827448-A4DA62A7-0665-4AD7-8D17-47A58B321289 Q33849695-2D372D32-83F3-48B8-8D7C-17B5AE589227 Q33906517-13D99FFF-6B56-4B77-9673-B5D7850B2EBB Q33920373-0A674D35-DA09-4054-8A9B-B2BC5452FFB5 Q34005720-0FD0D3A4-347A-4B9E-807C-D49860CF69C7 Q34067107-309C004E-8501-4F91-B6F4-4BEA1DE053DD Q34162206-E909811E-0AF3-4E11-AFE8-41078A476EE5 Q34295006-440F0C7C-BF90-408A-B610-19DDA1DF7AA2 Q34574482-3C89E418-E3CB-4864-A395-01C74DF78259 Q35097512-8BDE8529-CE6A-4044-B8BA-C240E2AA7C75 Q35097528-EEC91360-B88A-45D2-8EEA-ADF0A3997CC2 Q35124165-559ECE05-1365-450C-8134-14FD5EDCA4CF Q35142753-291B2DEA-9288-468D-9506-2F4B931F3138 Q35532337-D2F4BE51-1D33-4E15-8148-3C97A60BEE63 Q35580577-275FDAB7-40CE-4EEF-92BC-C5AC8AD5864C Q35597061-2D03CC6B-41E9-4D8A-9B12-C2F32EE33D4E Q35611793-5961660A-5714-47B7-97D3-35A33B0BA38F Q35618793-DD6DBE1C-B5EB-4369-86B8-C5A0352E0E64 Q35624672-ADF420A8-95BC-4DFD-8B70-6B6FF737B708 Q35758595-EE7D11B6-F062-492D-B961-4F81750EFCC3 Q35983428-87E74D44-E79F-4794-9855-6B35E8E4AD51 Q36099921-84FA36AD-FDAA-42D8-9E2D-22EB04BDB9E5

P2860

New approaches to the treatment of dense deposit disease.

http://www.wikidata.org/entity/Q36860946

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

New approaches to the treatment of dense deposit disease.

@en

type

label

New approaches to the treatment of dense deposit disease.

@en

prefLabel

New approaches to the treatment of dense deposit disease.

@en

P1433

Q36860946-3F9DE4D0-7E75-4334-96DE-1555C3D8A2E6

P1476

Q36860946-E462CAA5-442D-48A4-B077-6FB1148CBCCB

P2093

Q36860946-0763AAEA-A23C-42AA-B730-4916B56D024D

Q36860946-1112C58A-041E-4DEB-A2B1-1665030A958B

Q36860946-1F9432DD-4B95-46FB-A4A7-80DF4B49B87C

Q36860946-22542FE0-8B11-4107-BAFB-A3D40C13732A

Q36860946-3EF37E57-1A2F-4F13-8944-07372FF3B438

Q36860946-3F948FFA-85BB-4EC1-A7EF-AD232A6A2DCE

Q36860946-43942519-109E-4E52-8B34-037A75B6E01D

Q36860946-4F37C3E2-8364-4D65-8ED4-47EE8B511719

Q36860946-54BFD287-773F-4AD9-A96B-1FA008918828

Q36860946-560A0599-0AAC-4144-A74E-0C68FAACA0FE

P2860

Q36860946-008E1ECD-DD94-499F-BE7A-218072314209

Q36860946-031B456F-A7D3-4668-AE91-D98283F8090D

Q36860946-039A8DB8-E681-44E9-ADA9-F0D7D8B30D82

Q36860946-051D61DE-9821-47E7-85BE-299551CE66F5

Q36860946-0767B2EF-E6EF-42B0-AFC0-C79CEE524914

Q36860946-0C5D2345-C0A1-4078-BFEE-34792148DDB7

Q36860946-0F70B686-4D9E-45BC-AA61-76199FD4858F

Q36860946-173366C4-C102-477D-9AC0-1C88A51047AF

Q36860946-18D33D1D-B461-4FB1-93C4-0E2F3AEBB2A8

Q36860946-19289671-0ED1-42D1-85DD-83E0566D5A25

P304

Q36860946-29EAE6A1-7D05-4E09-B937-14EFDCEB4EDF

P31

Q36860946-D6EA8F89-E5F2-46BD-A719-7D97082AB6CE

P356

Q36860946-70697385-4BFA-409C-9C55-37A56A9DF753

P433

Q36860946-13F786C1-10AE-44E3-A0E2-830D4B9192A5

P478

Q36860946-9524D4C6-E669-4B8D-B741-80C20DD45B43

P50

Q36860946-244F992F-6E80-45DA-BF48-9B52AE3B37CA

Q36860946-7781B58B-1D71-45CD-844B-E25CD82A5BC8

Q36860946-8F96801B-339F-4FCD-915C-ABA83EF381F0

Q36860946-D9272488-EF79-4EF0-8C78-A2454C411B15

Q36860946-DCA91FCA-1AA3-4DF1-88BA-9F30D586A6E7

Q36860946-E335FF9A-4E7C-47AF-9B56-6FFE09490919

Q36860946-FEF549C0-E25F-4E2D-B684-B4E84C070C2F

P577

Q36860946-44F1715E-A13B-476B-B702-D73BC6A5DA11

P5875

Q36860946-4BBF58AF-5D81-46A4-A8EB-454D790E91B9

P698

Q36860946-169FB247-D1CD-4ED3-815B-E25E9BC4A0A6

P932

Q36860946-2D774F6B-AE65-424A-A431-6D05642C5964

P356

P1433

Journal of the American Society of Nephrology

P1476

New approaches to the treatment of dense deposit disease.

@en

P2093

Angelique L Rops

http://www.w3.org/2001/XMLSchema#string

Christoph Licht

http://www.w3.org/2001/XMLSchema#string

Dense Deposit Disease Focus Group

http://www.w3.org/2001/XMLSchema#string

Gregory S Hageman

http://www.w3.org/2001/XMLSchema#string

H Terence Cook

http://www.w3.org/2001/XMLSchema#string

Hans U Lutz

http://www.w3.org/2001/XMLSchema#string

Hope F Tully

http://www.w3.org/2001/XMLSchema#string

Jessy Alexander

http://www.w3.org/2001/XMLSchema#string

Joshua M Thurman

http://www.w3.org/2001/XMLSchema#string

Lynne D Lanning

http://www.w3.org/2001/XMLSchema#string

P2860

Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II)

A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration

Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome.

Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease)

Structure shows that a glycosaminoglycan and protein recognition site in factor H is perturbed by age-related macular degeneration-linked single nucleotide polymorphism

Dense deposit disease: a variant of membranoproliferative glomerulonephritis

Visual impairment caused by retinal abnormalities in mesangiocapillary (membranoproliferative) glomerulonephritis type II ("dense deposit disease")

Dense deposit disease is not a membranoproliferative glomerulonephritis

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15.

P304

2447-2456

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2007030356

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Santiago Rodriguez de Córdoba

John D. Lambris

Johan Van Der Vlag

Matthew C Pickering

P577

2007-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6163053

http://www.w3.org/2001/XMLSchema#string

P698

17675665

http://www.w3.org/2001/XMLSchema#string

P932

4853920

http://www.w3.org/2001/XMLSchema#string